MAFLD
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
PubMed • GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Lean patients, differential diagnosis: as per AGA 2022 guidelines, exclude other causes of liver disease, including other causes of fatty liver, such as HIV, lipodystrophy, lysosomal acid lipase deficiency, familial hypobetalipoproteinemia, and medication-induced hepatic steatosis (methotrexate, amiodarone, tamoxifen, and steroids), in patients... See more
mice lacking both fructokinase C and A are protected from fructose-induced fatty liver,
Thomas Jensen • Fructose and Sugar: A Major Mediator of Nonalcoholic Fatty Liver Disease - PMC
Fructose and Sugar: A Major Mediator of Nonalcoholic Fatty Liver Disease - PMC
Hugo R Rosenncbi.nlm.nih.govThe American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease
"obesity GLP-1" - Google News • ADA Says All Diabetes Patients Should Be Screened for Nonalcoholic ... - STAT
fructose component of sugar and HFCS appears to have a major role in inducing fatty liver by both stimulating de novo lipogenesis and blocking β-fatty acid oxidation. Evidence suggests these effects are due to the unique metabolism of fructose by fructokinase that leads to a fall in ATP with nucleotide turnover and uric acid generation.